Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
J Cardiovasc Transl Res. 2011 Apr;4(2):182-91. doi: 10.1007/s12265-010-9249-8. Epub 2011 Jan 7.
Intramyocardial bone marrow cell injection is currently being investigated as a new therapeutic option for the treatment of chronic myocardial ischemia. Experimental studies and early phase clinical trials established a favorable safety profile of this approach and suggested that bone marrow cell injection was associated with clinical and functional improvements. Recently, a randomized, double-blind, placebo-controlled trial demonstrated that intramyocardial bone marrow cell injection was associated with beneficial effects on myocardial perfusion and anginal symptoms. However, the mechanisms by which bone marrow cells may improve myocardial perfusion are only partially understood, and several issues remain to be addressed. This review aims to provide a summary of the current experience with bone marrow cell therapy as a novel treatment option for patients with chronic myocardial ischemia. Therefore, the most frequently used cell types will be reviewed along with the mechanisms through which bone marrow cells may improve myocardial perfusion and function. In addition, possible routes of delivery are compared, and the results of currently available experimental and clinical studies are discussed.
目前，骨髓细胞心肌内注射作为一种治疗慢性心肌缺血的新方法正在被研究。实验研究和早期临床试验确立了这种方法良好的安全性，并表明骨髓细胞注射与临床和功能改善相关。最近，一项随机、双盲、安慰剂对照试验表明，骨髓细胞心肌内注射与改善心肌灌注和心绞痛症状有关。然而，骨髓细胞改善心肌灌注的机制尚不完全清楚，仍有一些问题需要解决。这篇综述旨在提供骨髓细胞治疗作为慢性心肌缺血患者的一种新的治疗选择的最新经验总结。因此，本文将对最常使用的细胞类型进行综述，同时探讨骨髓细胞改善心肌灌注和功能的机制。此外，还比较了可能的给药途径，并讨论了目前可用的实验和临床研究的结果。
